(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2018 (11.05.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/083603 A1

(51) International Patent Classification:
*A61K 31/4545* (2006.01) *A61P 35/00* (2006.01)
*A61K 31/506* (2006.01)

(21) International Application Number:
PCT/IB2017/056787

(22) International Filing Date:
01 November 2017 (01.11.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/416,222 02 November 2016 (02.11.2016) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **FAIRHURST, Robin Alec**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **GRAUS PORTA, Diana**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **KINYAMU-AKUNDA, Jacqueline**; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, 07936 (US). **MAHL, Andreas Joerg**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **MANENTI, Luigi**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **WEISS, Andreas**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **WOLF, Armin**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). **WUERSCH, Kuno**; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*

WO 2018/083603 A1

(54) Title: COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS

(57) Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.